Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Translational and clinical advances in acute GVHD

John Koreth • 7 Jun 2021
EHA 2021
General Antibodies Itolizumab

John Koreth, MBBS, PhD, Dana-Farber Cancer Institute, Boston, MA, shares an update on the latest translational and clinical advances in the field of acute graft-versus-host disease (GvHD), in particular highlighting the potential future role of itolizumab in the frontline setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

John Koreth, MBBS, PhD, has received research support from Bristol Myers Squibb, Miltenyi, Clinigen, Amgen and Regeneron; has participated in advisory boards with Therakos, Cugene and Regeneron; and has participated in consultancy work with EMD Serono/Merck, Biolojic Design, Gentibio, Moderna Therapeutics and Equillium.

More from John Koreth

5:59
EQUATE: itolizumab for acute GvHD
John Koreth • 7 Jun 2021

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals